Article

Extreme genetic risk for type 1A diabetes in the post-genome era

Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Aurora, CO 80045-6511, USA.
Journal of Autoimmunity (Impact Factor: 7.02). 09/2008; 31(1):1-6. DOI: 10.1016/j.jaut.2008.03.003
Source: PubMed

ABSTRACT A series of genes and loci influencing the genetic risk of type 1A (immune-mediated) diabetes are now well characterized. These include genes of the major histocompatibility complex (MHC), polymorphisms 5' of the insulin gene, and PTPN22, as well as more recently defined loci from genome-wide association studies. By far the major determinants of risk for type 1A diabetes are genes within or linked to the MHC and in particular alleles of class II genes (HLA-DR, DQ, and DP). There is evidence that MHC class I alleles contribute and there are additional MHC-linked influences such that for a major subset of relatives of patients there is a risk as high as 80% for siblings, and for the general population a risk as high as 20% can be defined at birth just by analyzing the MHC. We believe the search for additional MHC loci will require analysis of the remarkable long-range identity (up to 9 million base pairs) of extended MHC haplotypes. Current prediction algorithms will likely be greatly improved for the general population when the additional contributing loci of the MHC are defined.

Download full-text

Full-text

Available from: Erin E Baschal, Sep 17, 2014
0 Followers
 · 
64 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In type 1 diabetes, insulin producing pancreatic β-cells are attacked and destroyed by autoreactive T cells, which causes major impairments of blood glucose metabolism and finally development of life-threatening complications. Currently, the treatment of this devastating disease is based on the substitution of insulin and thus can be considered palliative. Curative treatment approaches by contrast need to target the underlying causes of disease development: in this case, the autoreactive immune system and the loss of active β-cell mass. In recent years, several clinical trials have been performed studying the effects of diverse immunomodulating agents in order to halt the autoreactive immune response or finding paths to repopulate β-cell mass that could restore euglycemia. While some of the treatments showed remarkable outcomes, most of the studies failed to improve the course of disease. The reason might be that none of the candidates currently under investigation are potent enough at tolerable dosages to hold the key for the cure. Subsequently, the idea of combining defined substances has evolved in order to detect synergistic effects and improve the strength of the therapeutic potential. Observations from mouse models and clinical experience from various other diseases where combination therapies often constitute the standard treatment strongly support this hypothesis. Here, we discuss promising monotherapeutic approaches, summarize current clinical trials and propose a rationale on how to prioritize different combinations of treatments.
    International immunopharmacology 12/2010; 10(12):1491-5. DOI:10.1016/j.intimp.2010.07.008 · 2.71 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: It is known that autoimmune diseases cumulatively affect 5–10% of the general population.Although knowledge of pathogenesis has become more refined, laboratory diagnosis more accurate, and therapy more effective, the reasons for the female preponderance of these conditions remain unclear. The most intriguing theory to explain the female preponderance is currently related to sex chromosomes, as women with autoimmune diseases manifest a higher rate of circulating cells with a single X chromosome (i.e. X monosomy). In addition, there have been several reports on the role of X chromosome gene dosage through inactivation or duplication in autoimmunity. Taken together, sex chromosome changes might constitute the common trait of the susceptibility to autoimmune diseases.
    Journal of Autoimmunity 08/2009; DOI:10.1016/j.jaut.2009.03.005 · 7.02 Impact Factor
  • Conference Paper: Virtual VHDL laboratory
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reports on a prototype, network-based virtual laboratory that allows geographically distributed users to share and run existing tools via a standard Web browser. The software infrastructure for the virtual laboratory is described and ongoing application of this infrastructure to digital systems design and education is discussed
    Electronics, Circuits and Systems, 1998 IEEE International Conference on; 02/1998